Form 4: Maravai LifeSciences Director Benjamin Daverman Reports Acquisition of Restricted Stock Units

Director Benjamin Daverman reports acquiring 20,645 Class A Common Stock restricted stock units in Maravai LifeSciences Holdings, Inc.

Summary

• On May 23, 2024, Benjamin James Daverman, a director of Maravai LifeSciences Holdings, Inc., acquired 20,645 shares of Class A Common Stock.
• These shares were granted as restricted stock units.
• The price per share was $10.78.
• The restricted stock units vest in full upon the earlier of one year from the grant date or the date of the 2025 Maravai LifeSciences Holdings, Inc. annual meeting of stockholders.
• Following the transaction, Daverman beneficially owns 48,916 shares, held indirectly for the benefit of a GTCR-affiliated entity.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a standard disclosure of insider activity. The acquisition of shares by a director is generally viewed as a positive, but the disclaimer of pecuniary interest tempers the enthusiasm.

Positives

• The acquisition of restricted stock units by a director can be seen as a positive sign, indicating confidence in the company's future performance.

Future Outlook

The restricted stock units vest in full upon the earlier of one year from the date of grant or the date of the 2025 Maravai LifeSciences Holdings, Inc. annual meeting of stockholders.

Management Comments

• The Reporting Person disclaims any pecuniary interest in the securities, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of the securities for purposes of Section 16.

Industry Context

This filing is a routine disclosure related to insider transactions, which are common in publicly traded companies. It provides transparency into the actions of company insiders.

Comparison to Industry Standards

• Form 4 filings are standard practice for publicly traded companies in the US, ensuring transparency of insider transactions.
• Similar filings are made by directors and officers of companies like Thermo Fisher Scientific and Danaher Corporation when they acquire or dispose of company stock.

Stakeholder Impact

• The transaction could have a minor positive impact on shareholder sentiment, as it indicates a director's confidence in the company.

Key Dates